Drug intelligence / Profile preview

AVCN319301a

Development stage: Unknown
Lead developer: Avicanna
Modality: Small Molecules
Administration: Oral

Overview

AVCN319301a is a cannabinoid-based pharmaceutical candidate developed by Avicanna for the treatment of osteoarthritic pain. It is an oral formulation currently in Phase II/III clinical development. The drug utilizes a proprietary cannabinoid delivery system to target pain pathways associated with osteoarthritis. While the specific molecular mechanism (e.g., specific cannabinoid ratios or receptor targets) is not detailed in public pipeline summaries, it is part of Avicanna's pharmaceutical pipeline focused on evidence-based cannabinoid therapies.

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on AVCN319301a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVCN319301a.

Explore the full profile